Form 4: Collegium Pharma CMO Sells $672K in Stock

Collegium Pharmaceutical's EVP and Chief Medical Officer, Thomas B. Smith, sold 17,478 shares of common stock for approximately $672,000.

Summary

• Thomas B. Smith, the Executive Vice President and Chief Medical Officer of Collegium Pharmaceutical, Inc. (COLL), reported the sale of 17,478 shares of the company's common stock.
• The transaction occurred on August 29, 2025, at a weighted average price of $38.4241 per share, totaling approximately $671,999.99.
• The shares were sold in multiple transactions within a price range of $38.37 to $38.48.
• Following this sale, Mr. Smith directly beneficially owns 70,264 shares of Collegium Pharmaceutical common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale by an insider, even if pre-planned, can be viewed with slight caution as it reduces direct ownership. However, the 10b5-1 plan mitigates the negative signal, making it a neutral-to-slightly-negative event rather than a strong negative indicator.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale for personal financial management rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity stake of a key executive in the company.
• The sale represents a reduction of 17,478 shares from the Chief Medical Officer's direct beneficial ownership.

Risks

• Insider sales, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to questions about executive confidence or future company prospects.

Industry Context

This transaction is a routine insider filing and does not directly reflect broader industry trends. However, insider activity is consistently monitored by investors for sentiment within the pharmaceutical sector, particularly for companies like Collegium Pharmaceutical focused on pain management and other specialized areas.

Related Party Transactions

• Thomas B. Smith, an executive officer of Collegium Pharmaceutical, Inc., sold shares of the company's common stock.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, although the 10b5-1 plan suggests it is a routine diversification or liquidity event rather than a loss of confidence in the company's future.

Key Dates

Recommendation

While an insider sale typically warrants caution, the transaction was executed under a Rule 10b5-1 plan, suggesting it was a pre-scheduled event for personal financial planning rather than a reaction to new, adverse information. The remaining beneficial ownership of 70,264 shares indicates continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity without immediate alarm.

Keywords

Collegium Pharmaceutical, COLL, Insider Trading, Form 4, Stock Sale, Thomas B. Smith, EVP Chief Medical Officer, Pharmaceuticals, Equity Transaction, 10b5-1 Plan